Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionSUMO transferase activity

MDM2 HDAC7 PML

6.77e-0536443GO:0019789
GeneOntologyMolecularFunctionnon-membrane spanning protein tyrosine phosphatase activity

PTPN2 PTPN4

3.09e-0412442GO:0004726
GeneOntologyMolecularFunctionubiquitin-like protein transferase activity

DZIP3 RNF31 MDM2 HDAC7 RNF43 PML

8.52e-04512446GO:0019787
GeneOntologyMolecularFunctiontransition metal ion binding

MGAT5 ZZZ3 HDAC10 DRP2 RNF31 MDM2 ADA CYP26A1 PML

9.75e-041189449GO:0046914
GeneOntologyMolecularFunctionaminoacyltransferase activity

DZIP3 RNF31 MDM2 HDAC7 RNF43 PML

1.04e-03532446GO:0016755
GeneOntologyMolecularFunctionmodification-dependent protein binding

DZIP3 ZZZ3 RNF31 PML

1.08e-03206444GO:0140030
GeneOntologyMolecularFunctionhistone deacetylase activity

HDAC10 HDAC7

1.27e-0324442GO:0004407
GeneOntologyMolecularFunctionprotein lysine deacetylase activity

HDAC10 HDAC7

1.38e-0325442GO:0033558
GeneOntologyMolecularFunctionprotein tyrosine phosphatase activity

PTPN2 PTPN4 ACP4

1.51e-03103443GO:0004725
GeneOntologyMolecularFunctionretinoic acid binding

UGT1A10 CYP26A1

1.73e-0328442GO:0001972
GeneOntologyMolecularFunctionubiquitin-like protein ligase activity

DZIP3 RNF31 MDM2 RNF43 PML

1.76e-03398445GO:0061659
GeneOntologyMolecularFunctionubiquitin-like protein binding

RNF31 MDM2 PML

2.81e-03128443GO:0032182
GeneOntologyMolecularFunctionzinc ion binding

ZZZ3 HDAC10 DRP2 RNF31 MDM2 ADA PML

3.11e-03891447GO:0008270
GeneOntologyMolecularFunctiondeacetylase activity

HDAC10 HDAC7

3.51e-0340442GO:0019213
GeneOntologyMolecularFunctionhydrolase activity, acting on carbon-nitrogen (but not peptide) bonds

HDAC10 ADA HDAC7

4.07e-03146443GO:0016810
GeneOntologyMolecularFunctionhistone deacetylase binding

MTA1 HDAC10 DNMT3B

4.15e-03147443GO:0042826
DomainHist_deacetyl

HDAC10 HDAC7

2.81e-0411432PF00850
DomainHis_deacetylse_dom

HDAC10 HDAC7

2.81e-0411432IPR023801
Domain-

HDAC10 HDAC7

2.81e-04114323.40.800.20
DomainHis_deacetylse

HDAC10 HDAC7

2.81e-0411432IPR000286
DomainZF_RING_1

DZIP3 RNF31 MDM2 RNF43 PML

5.26e-04291435PS00518
Domain-

DZIP3 ZFYVE26 MDM2 RNF43 PML DNMT3B

5.36e-044494363.30.40.10
DomainZF_RING_2

DZIP3 RNF31 MDM2 RNF43 PML

5.86e-04298435PS50089
DomainZnf_RING/FYVE/PHD

DZIP3 ZFYVE26 MDM2 RNF43 PML DNMT3B

6.01e-04459436IPR013083
DomainRING

DZIP3 RNF31 MDM2 RNF43 PML

6.51e-04305435SM00184
DomainEMI

SSPOP EMID1

6.89e-0417432PS51041
DomainZZ

ZZZ3 DRP2

7.74e-0418432PF00569
DomainZF_ZZ_2

ZZZ3 DRP2

7.74e-0418432PS50135
DomainZF_ZZ_1

ZZZ3 DRP2

7.74e-0418432PS01357
DomainZnf_ZZ

ZZZ3 DRP2

8.64e-0419432IPR000433
DomainZnF_ZZ

ZZZ3 DRP2

8.64e-0419432SM00291
DomainZnf_RING

DZIP3 RNF31 MDM2 RNF43 PML

8.78e-04326435IPR001841
Domainzf-RanBP

RNF31 MDM2

1.16e-0322432PF00641
DomainZF_RANBP2_2

RNF31 MDM2

1.27e-0323432PS50199
DomainZF_RANBP2_1

RNF31 MDM2

1.38e-0324432PS01358
DomainEGF_Ca-bd_CS

DLK2 UMOD CRB1

1.44e-0397433IPR018097
DomainZnf_RanBP2

RNF31 MDM2

1.50e-0325432IPR001876
DomainEGF_CA

DLK2 UMOD CRB1

1.53e-0399433PS01187
DomainASX_HYDROXYL

DLK2 UMOD CRB1

1.57e-03100433PS00010
DomainEGF-type_Asp/Asn_hydroxyl_site

DLK2 UMOD CRB1

1.86e-03106433IPR000152
DomainhEGF

DLK2 CRB1

1.88e-0328432PF12661
DomainEGF_3

DLK2 UMOD SSPOP CRB1

2.05e-03235434PS50026
DomainEGF_1

DLK2 UMOD SSPOP CRB1

2.76e-03255434PS00022
DomainEGF_CA

DLK2 UMOD CRB1

2.77e-03122433SM00179
DomainEGF-like_Ca-bd_dom

DLK2 UMOD CRB1

2.90e-03124433IPR001881
DomainMyb_DNA-binding

MTA1 ZZZ3

2.94e-0335432PF00249
DomainEGF

DLK2 UMOD CRB1

3.04e-03126433PF00008
DomainPTPc

PTPN2 PTPN4

3.10e-0336432SM00194
DomainEGF_2

DLK2 UMOD SSPOP CRB1

3.17e-03265434PS01186
DomainTYR_PHOSPHATASE_PTP

PTPN2 PTPN4

3.63e-0339432PS50055
DomainPTPase_domain

PTPN2 PTPN4

4.01e-0341432IPR000242
DomainY_phosphatase

PTPN2 PTPN4

4.01e-0341432PF00102
DomainSANT

MTA1 ZZZ3

5.91e-0350432SM00717
Domainzf-RING_2

DZIP3 RNF43

6.38e-0352432PF13639
DomainSANT/Myb

MTA1 ZZZ3

6.38e-0352432IPR001005
DomainPTPc_motif

PTPN2 PTPN4

8.15e-0359432SM00404
DomainTyr_Pase_cat

PTPN2 PTPN4

8.15e-0359432IPR003595
DomainTSP_1

THSD7B SSPOP

9.25e-0363432PF00090
DomainTSP1

THSD7B SSPOP

9.82e-0365432SM00209
DomainTSP1_rpt

THSD7B SSPOP

9.82e-0365432IPR000884
DomainTSP1

THSD7B SSPOP

9.82e-0365432PS50092
PathwayPID_TAP63_PATHWAY

MDM2 ADA SSPOP PML

1.16e-0554374M256
PathwayPID_P73PATHWAY

MDM2 ADA RNF43 PML

5.24e-0579374M19
PathwayREACTOME_SUMOYLATION

MTA1 MDM2 HDAC7 PML DNMT3B

7.46e-05169375MM14919
PathwayREACTOME_SUMOYLATION

MTA1 MDM2 HDAC7 PML DNMT3B

1.26e-04189375M27214
Pubmed

MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53.

MDM2 PML

1.56e-06244214507915
Pubmed

Physical and functional interactions between PML and MDM2.

MDM2 PML

1.56e-06244212759344
Pubmed

MTA1 coregulator regulates p53 stability and function.

MTA1 MDM2

4.69e-06344219837670
Pubmed

Signal-dependent regulation of transcription by histone deacetylase 7 involves recruitment to promyelocytic leukemia protein nuclear bodies.

HDAC7 PML

4.69e-06344218463162
Pubmed

PML3 Orchestrates the Nuclear Dynamics and Function of TIP60.

MDM2 PML

4.69e-06344219150978
Pubmed

DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer.

MDM2 DNMT3B

4.69e-06344225122426
Pubmed

Interaction of uromodulin and complement factor H enhances C3b inactivation.

CFH UMOD

4.69e-06344227113631
Pubmed

DNMT3B activates FGFR3-mediated endoplasmic reticulum stress by regulating PTPN2 promoter methylation to promote the development of atherosclerosis.

PTPN2 DNMT3B

4.69e-06344237462502
Pubmed

Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.

HDAC7 PML

4.69e-06344218625722
Pubmed

Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization.

MDM2 PML

4.69e-06344212915590
Pubmed

Evidence for separate ND10-binding and homo-oligomerization domains of Sp100.

MDM2 PML

9.37e-06444211112690
Pubmed

SnoN activates p53 directly to regulate aging and tumorigenesis.

MDM2 PML

9.37e-06444222805162
Pubmed

PML regulates p53 stability by sequestering Mdm2 to the nucleolus.

MDM2 PML

9.37e-06444215195100
Pubmed

BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction.

MDM2 PML

9.37e-06444222869143
Pubmed

The DNA methyltransferase DNMT3C protects male germ cells from transposon activity.

PIWIL2 DNMT3B

1.56e-05544227856912
Pubmed

PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.

PML DNMT3B

1.56e-05544226595813
Pubmed

β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.

HDAC7 PML

2.34e-05644222155184
Pubmed

A bio-orthogonal linear ubiquitin probe identifies STAT3 as a direct substrate of OTULIN in glioblastoma.

PTPN2 RNF31

3.27e-05744236660824
Pubmed

Mad1 destabilizes p53 by preventing PML from sequestering MDM2.

MDM2 PML

3.27e-05744230948704
Pubmed

SUMO E3 ligase activity of TRIM proteins.

MDM2 PML

4.36e-05844220972456
Pubmed

Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes.

MDM2 PML

4.36e-05844212393906
Pubmed

The Epigenetic Factor Landscape of Developing Neocortex Is Regulated by Transcription Factors Pax6→ Tbr2→ Tbr1.

MTA1 HDAC10 HDAC7 DNMT3B

4.71e-0515744430186101
Pubmed

Proteomic analysis of murine Piwi proteins reveals a role for arginine methylation in specifying interaction with Tudor family members.

TDRD7 PIWIL2

6.99e-051044219584108
Pubmed

Histone Deacetylase 1 Is Essential for Rod Photoreceptor Differentiation by Regulating Acetylation at Histone H3 Lysine 9 and Histone H4 Lysine 12 in the Mouse Retina.

HDAC10 HDAC7

6.99e-051044228028172
Pubmed

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

PTPN2 ADA HDAC7 DOK3 DNMT3B

7.08e-0534244523128233
Pubmed

Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress.

MDM2 PML

8.54e-051144223169665
Pubmed

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.

MTA1 DNMT3B

1.02e-041244223708667
Pubmed

Establishment of a Wheat Cell-Free Synthesized Protein Array Containing 250 Human and Mouse E3 Ubiquitin Ligases to Identify Novel Interaction between E3 Ligases and Substrate Proteins.

DZIP3 MDM2

1.21e-041344227249653
Pubmed

Histone deacetylase expression patterns in developing murine optic nerve.

HDAC10 HDAC7

1.41e-041444225011550
Pubmed

Genome-wide association study of pancreatic cancer in Japanese population.

THSD7B RNF43

1.41e-041444220686608
Pubmed

Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the charge and care consortia.

CFH RNF43

1.41e-041444223620142
Pubmed

Subcellular localization of intracellular protein tyrosine phosphatases in T cells.

PTPN2 PTPN4

1.41e-041444210940933
Pubmed

Prediction of the coding sequences of mouse homologues of FLJ genes: the complete nucleotide sequences of 110 mouse FLJ-homologous cDnas identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

ZZZ3 RNF31 HDAC7

1.74e-048544315449545
Pubmed

Cloning and characterization of PTP-K1, a novel nonreceptor protein tyrosine phosphatase highly expressed in bone marrow.

PTPN2 PTPN4

1.86e-04164428875997
Pubmed

Mouse MAELSTROM: the link between meiotic silencing of unsynapsed chromatin and microRNA pathway?

TDRD7 PIWIL2

1.86e-041644216787967
Pubmed

Transformation of the Transcriptomic Profile of Mouse Periocular Mesenchyme During Formation of the Embryonic Cornea.

MTA1 CYP26A1

2.10e-041744230786278
Pubmed

HDAC family: What are the cancer relevant targets?

HDAC10 HDAC7

2.36e-041844218824292
Pubmed

Jmjd5 functions as a regulator of p53 signaling during mouse embryogenesis.

MDM2 PML

2.36e-041844226334721
Pubmed

Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.

HDAC10 MDM2

2.64e-041944214578343
Pubmed

The TDRD9-MIWI2 complex is essential for piRNA-mediated retrotransposon silencing in the mouse male germline.

PIWIL2 DNMT3B

2.93e-042044220059948
Pubmed

Robust p53 Stabilization Is Dispensable for Its Activation and Tumor Suppressor Function.

MDM2 PML

2.93e-042044233323382
Pubmed

Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity.

MDM2 PML

3.24e-042144221040902
Pubmed

Systematic analysis of dimeric E3-RING interactions reveals increased combinatorial complexity in human ubiquitination networks.

DZIP3 MDM2 PML

3.24e-0410544322493164
Pubmed

Loss of SET reveals both the p53-dependent and the p53-independent functions in vivo.

MDM2 PML

3.89e-042344230858352
Pubmed

The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway.

RNF31 MDM2

3.89e-042344230017913
Pubmed

Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells.

MTA1 PML

4.24e-042444218454139
Pubmed

A comprehensive framework of E2-RING E3 interactions of the human ubiquitin-proteasome system.

MDM2 RNF43 PML

4.56e-0411844319690564
Pubmed

The functional interactome landscape of the human histone deacetylase family.

MTA1 HDAC10 HDAC7 PML

4.88e-0428944423752268
Pubmed

TDRD5 is required for retrotransposon silencing, chromatoid body assembly, and spermiogenesis in mice.

TDRD7 PIWIL2

6.21e-042944221383078
Pubmed

TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2.

MDM2 PML

8.55e-043444237139431
Pubmed

Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors.

MTA1 PML

9.06e-043544222325351
Pubmed

Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse.

MTA1 PRAME

9.06e-043544219389355
Pubmed

An Oct4-centered protein interaction network in embryonic stem cells.

MTA1 ZZZ3 PML

1.25e-0316744320362541
GeneFamilyZinc fingers ZZ-type|Lysine acetyltransferases

ZZZ3 DRP2

5.78e-041836291
GeneFamilyProtein tyrosine phosphatases, non-receptor type

PTPN2 PTPN4

5.78e-0418362812
GeneFamilyZinc fingers RANBP2-type |RNA binding motif containing

RNF31 MDM2

7.90e-042136289
GeneFamilyRing finger proteins

DZIP3 RNF31 RNF43 PML

2.10e-0327536458
GeneFamilyGATA zinc finger domain containing|Myb/SANT domain containing

MTA1 ZZZ3

4.98e-0353362532
CoexpressionGAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_7DY_UP

TDRD7 REC8 ZFYVE26 RNF31 ADA PML

7.83e-06292436M41140
CoexpressionHALLMARK_INTERFERON_GAMMA_RESPONSE

TDRD7 CFH PTPN2 RNF31 PML

1.87e-05200435M5913
CoexpressionGAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_3DY_UP

TDRD7 REC8 ZFYVE26 RNF31 ADA

2.89e-05219435M41142
ToppCellBasal_cells-IPF_01|World / lung cells shred on cell class, cell subclass, sample id

DLK2 THSD7B UGT1A10 CYP26A1

1.97e-0516643423c04d1fba0c1733ccd0e4378fae2edde4fd0a7b
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

UMOD PTPN4 MGAT5 RNF43

2.42e-05175434e5467dacf81f1f913b1719931cf1a7331434a7e7
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ATP13A4 DRP2 DNAH10 SSPOP

2.95e-05184434ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ATP13A4 DRP2 DNAH10 SSPOP

2.95e-051844342cbed6462fea2622871bb7e49b0df3d984239281
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ATP13A4 DRP2 DNAH10 SSPOP

2.95e-051844342b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell10x3'2.3-week_12-13-Lymphocytic_NK-T_NK-ILC_precursor|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

CFH PTPN4 SSPOP CYP26A1

3.14e-05187434f31d865ce2a21bdf64dbe29ee3e4505ab482604a
ToppCell(6)_ILC|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)

CFH CYP26A1 EMID1 DNMT3B

3.21e-05188434de7cb273899d0e0748c85f45c6b5e7f0642ab057
ToppCell(6)_ILC|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)

CFH CYP26A1 EMID1 DNMT3B

3.21e-05188434f4734d5b703678670ece204a0519cf015e180a6e
ToppCellBasal_cells-IPF_02|World / lung cells shred on cell class, cell subclass, sample id

CFH DLK2 RNF43 UGT1A10

3.41e-05191434a98915bad9a4a61dd4cbca798914849b805f4a19
ToppCellkidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

UMOD PTPN4 MGAT5 RNF43

3.48e-05192434ee27d27e3d269764dbe8711d0b37ff9331a298a9
ToppCelldistal-3-Epithelial-Ionocyte|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

RNF43 ETNK2 CYP26A1 DNMT3B

3.77e-051964346ed146481dd04fb271eadc47d68eb3ae38986db6
ToppCelldistal-Epithelial-Ionocyte-3|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

RNF43 ETNK2 CYP26A1 DNMT3B

3.85e-051974347a2cd970fe0866057999e40d15367b2b3324ae59
ToppCelldistal-Epithelial-Ionocyte|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

RNF43 ETNK2 CYP26A1 DNMT3B

3.85e-0519743411a5d2db2561d045756980ead61e1211c7dda100
DrugDimethadione [695-53-4]; Down 200; 31uM; PC3; HT_HG-U133A

RNF31 ADA HDAC7 PRAME ETNK2 BRF2

1.97e-061954464607_DN
DrugDiltiazem hydrochloride [33286-22-5]; Up 200; 8.8uM; MCF7; HT_HG-U133A

DLK2 MDM2 PRAME EMID1 BRF2 PML

2.09e-061974461532_UP
Drugclozapine; Up 200; 10uM; HL60; HT_HG-U133A

REC8 DRP2 GRM4 HDAC7 CRB1 PML

2.09e-061974462689_UP
Drug16-phenyl tetranor Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A

DZIP3 DRP2 MDM2 HDAC7 EMID1 PML

2.15e-061984467541_UP
DrugVitexin [3681-93-4]; Up 200; 9.2uM; MCF7; HT_HG-U133A

REC8 DLK2 FBXO41 MGAT5 DRP2 GRM4

2.15e-061984464413_UP
DrugAC1NV99J

MTA1 HDAC10 HDAC7

3.71e-0616443CID005474719
DrugAC1L1EXH

MTA1 HDAC10 HDAC7

5.38e-0618443CID000002992
DrugNSC3852

MTA1 HDAC10 HDAC7

7.50e-0620443CID000019103
DrugQuercetine dihydrate [6151-25-3]; Down 200; 11.8uM; HL60; HT_HG-U133A

TDRD7 REC8 PTPN4 RNF31 PML

3.28e-051914452499_DN
DrugProbenecid [57-66-9]; Up 200; 14uM; MCF7; HT_HG-U133A

REC8 GRM4 PRAME EMID1 PML

3.62e-051954454771_UP
DrugFlumethasone [2135-17-3]; Up 200; 9.8uM; PC3; HT_HG-U133A

FBXO41 MTA1 GRM4 EMID1 PML

3.62e-051954454272_UP
DrugTrimethobenzamide hydrochloride [554-92-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A

DLK2 FBXO41 MDM2 ETNK2 PML

3.62e-051954454180_DN
DrugTerconazole [67915-31-5]; Down 200; 7.6uM; MCF7; HT_HG-U133A

DLK2 MDM2 ETNK2 EMID1 PML

3.71e-051964454407_DN
DrugVinpocetine [42971-09-5]; Up 200; 11.4uM; PC3; HT_HG-U133A

REC8 MGAT5 MDM2 HDAC7 BRF2

3.81e-051974455859_UP
DrugDosulepin hydrochloride [897-15-4]; Up 200; 12uM; MCF7; HT_HG-U133A

MGAT5 GRM4 PRAME EMID1 PML

3.81e-051974452864_UP
Drugcopper(II) sulfate pentahydrate; Down 200; 100uM; MCF7; HG-U133A

DZIP3 FBXO41 HDAC7 RNF43 DOK3

3.81e-05197445438_DN
DrugPhenformin hydrochloride [834-28-6]; Up 200; 16.6uM; HL60; HT_HG-U133A

REC8 DZIP3 MDM2 DOK3 PML

3.81e-051974452350_UP
Drug(+) -Levobunolol hydrochloride [47141-41-3]; Down 200; 12.2uM; HL60; HT_HG-U133A

ZFYVE26 MTA1 MDM2 NME8 PML

3.90e-051984453016_DN
DrugBendroflumethiazide [73-48-3]; Up 200; 9.4uM; MCF7; HT_HG-U133A

REC8 DLK2 GRM4 DOK3 PML

3.99e-051994453934_UP
DrugEtanidazole [22668-01-5]; Up 200; 18.6uM; MCF7; HT_HG-U133A

FBXO41 MDM2 GRM4 RNF43 PML

3.99e-051994456072_UP
DrugLymecycline [992-21-2]; Up 200; 6.6uM; HL60; HT_HG-U133A

MTA1 DRP2 MDM2 HDAC7 DNMT3B

3.99e-051994452953_UP
DrugDiphenylpyraline hydrochloride [132-18-3]; Up 200; 12.6uM; HL60; HT_HG-U133A

REC8 MTA1 HDAC7 EMID1 PML

3.99e-051994452205_UP
DrugNSC105014

ACP4 MTA1 MDM2 ADA

6.03e-05110444CID000001546
Drugtrapoxin

MTA1 HDAC10 HDAC7

1.93e-0458443CID000121875
Drug2-methyl-6-styrylpyridine

ACP4 GRM4

3.27e-0414442CID000235382
Drug2ccu

CFH UMOD

4.31e-0416442CID006102789
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

DZIP3 FBXO41 ZFYVE26 HDAC7

4.44e-041854441022_UP
DrugDiloxanide furoate [3736-81-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A

DLK2 MDM2 RNF43 PML

4.63e-041874445025_UP
DrugHexetidine [141-94-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A

REC8 MGAT5 MDM2 PML

4.63e-041874445420_UP
DrugTrapoxin B

MTA1 HDAC10 PML

4.81e-0479443CID000005532
DrugTrichostatin A, Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A

REC8 DZIP3 MDM2 EMID1

4.82e-041894442672_UP
Drugsulforaphane

MTA1 HDAC10 HDAC7 UGT1A10

4.82e-04189444CID000005350
DrugEllipticine [519-23-3]; Up 200; 16.2uM; MCF7; HT_HG-U133A

MTA1 MDM2 CYP26A1 PML

4.91e-041904446253_UP
DrugSimvastatin [79902-63-9]; Up 200; 9.6uM; PC3; HT_HG-U133A

CFH DLK2 RNF43 PML

5.11e-041924444244_UP
DrugHyoscyamine (L) [101-31-5]; Down 200; 13.8uM; MCF7; HT_HG-U133A

FBXO41 PTPN2 RNF43 PML

5.11e-041924442271_DN
DrugTranylcypromine hydrochloride [1986-47-6]; Down 200; 23.6uM; PC3; HT_HG-U133A

ZNF133 RNF31 PRAME BRF2

5.11e-041924442101_DN
Drug2-Aminobenzenesulfonamide [3306-62-5]; Down 200; 23.2uM; MCF7; HT_HG-U133A

FBXO41 HDAC7 ETNK2 EMID1

5.11e-041924443400_DN
DrugSuccinylsulfathiazole [116-43-8]; Down 200; 11.2uM; HL60; HT_HG-U133A

PTPN2 ADA BRF2 PML

5.21e-041934442166_DN
DrugChlorpheniramine maleate [113-92-8]; Up 200; 10.2uM; PC3; HT_HG-U133A

FBXO41 PTPN2 ETNK2 PML

5.21e-041934442055_UP
DrugLY 294002; Up 200; 10uM; HL60; HT_HG-U133A

REC8 DZIP3 NME8 CRB1

5.31e-041944446195_UP
Drugprazosin hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA

FBXO41 MDM2 ETNK2 PML

5.31e-04194444942_UP
DrugAmiodarone hydrochloride [19774-82-4]; Down 200; 5.8uM; HL60; HT_HG-U133A

EMID1 DOK3 PML DNMT3B

5.31e-041944442434_DN
DrugMethoxy-8-psoralen [298-81-7]; Up 200; 18.6uM; MCF7; HT_HG-U133A

DLK2 DRP2 MDM2 PML

5.31e-041944443302_UP
DrugFosfosal [6064-83-1]; Down 200; 18.4uM; PC3; HT_HG-U133A

MTA1 GRM4 HDAC7 PML

5.31e-041944444239_DN
Drug5230742; Up 200; 17uM; MCF7; HT_HG-U133A_EA

ZFYVE26 MDM2 ETNK2 PML

5.31e-04194444862_UP
DrugOxethazaine [126-27-2]; Down 200; 8.6uM; PC3; HT_HG-U133A

PTPN2 MTA1 GRM4 PML

5.31e-041944444246_DN
DrugLY 294002; Up 200; 10uM; HL60; HT_HG-U133A

DZIP3 MDM2 HDAC7 NME8

5.31e-041944442687_UP
DrugFusaric acid [536-69-6]; Up 200; 22.4uM; HL60; HT_HG-U133A

PTPN2 MDM2 HDAC7 PML

5.31e-041944441308_UP
DrugMetolazone [17560-51-9]; Up 200; 11uM; MCF7; HT_HG-U133A

FBXO41 HDAC7 CYP26A1 PML

5.42e-041954445392_UP
DrugMoxisylyte hydrochoride [964-52-3]; Up 200; 12.6uM; PC3; HT_HG-U133A

DZIP3 ETNK2 EMID1 DNMT3B

5.42e-041954447255_UP
DrugTolnaftate [2398-96-1]; Down 200; 13uM; MCF7; HT_HG-U133A

PTPN2 MTA1 RNF31 MDM2

5.42e-041954441501_DN
DrugEthynylestradiol 3-methyl ether [72-33-3]; Up 200; 12.8uM; MCF7; HT_HG-U133A

REC8 GRM4 EMID1 PML

5.42e-041954444792_UP
DrugFluticasone propionate [80474-14-2]; Down 200; 8uM; PC3; HT_HG-U133A

DLK2 MDM2 ETNK2 PML

5.42e-041954444011_DN
DrugThalidomide [50-35-1]; Up 200; 15.4uM; MCF7; HT_HG-U133A

MDM2 ETNK2 DOK3 PML

5.42e-041954445990_UP
DrugLoracarbef [121961-22-6]; Up 200; 10.8uM; HL60; HT_HG-U133A

FBXO41 MTA1 RNF31 PML

5.42e-041954442970_UP
DrugLidoflazine [3416-26-0]; Down 200; 8.2uM; MCF7; HT_HG-U133A

MTA1 RNF43 EMID1 PML

5.42e-041954443201_DN
Drugrotenone; Up 200; 1uM; MCF7; HT_HG-U133A

MTA1 NME8 ETNK2 PML

5.42e-041954445943_UP
DrugPronethalol hydrochloride [51-02-5]; Down 200; 15uM; PC3; HT_HG-U133A

DZIP3 MTA1 MDM2 PML

5.42e-041954443984_DN
DrugPropofol [2078-54-8]; Down 200; 22.4uM; PC3; HT_HG-U133A

MTA1 HDAC7 PML DNMT3B

5.42e-041954446707_DN
DrugCrotamiton [483-63-6]; Down 200; 19.6uM; HL60; HT_HG-U133A

REC8 ADA NME8 PML

5.42e-041954443050_DN
DrugFluorometholone [426-13-1]; Up 200; 10.6uM; PC3; HT_HG-U133A

GRM4 RNF43 ETNK2 CRB1

5.52e-041964445771_UP
DrugFillalbin [4540-25-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A

REC8 DLK2 FBXO41 PML

5.52e-041964444172_DN
DrugMetanephrine hydrochloride DL [881-95-8]; Up 200; 17.2uM; MCF7; HT_HG-U133A

PTPN2 MDM2 PRAME PML

5.52e-041964441515_UP
DrugThioproperazine dimesylate [2347-80-0]; Down 200; 6.2uM; MCF7; HT_HG-U133A

MTA1 MDM2 ETNK2 PML

5.52e-041964442236_DN
DrugBaclofen (R,S) [1134-47-0]; Up 200; 18.8uM; MCF7; HT_HG-U133A

PTPN2 MTA1 EMID1 PML

5.52e-041964441536_UP
DrugSulfisoxazole [127-69-5]; Up 200; 15uM; MCF7; HT_HG-U133A

REC8 FBXO41 MDM2 PML

5.52e-041964445622_UP
DrugAllantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A

DLK2 FBXO41 RNF31 PML

5.52e-041964445052_UP
DrugEpicatechin-(-) [154-23-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A

MDM2 ETNK2 CYP26A1 PML

5.52e-041964444419_DN
DrugCisapride [81098-60-4]; Down 200; 8.6uM; HL60; HT_HG-U133A

ZNF133 ZFYVE26 EMID1 DNMT3B

5.52e-041964442443_DN
DrugLithocholic acid [434-13-9]; Up 200; 10.6uM; PC3; HT_HG-U133A

DLK2 MDM2 GRM4 ADA

5.52e-041964444551_UP
DrugProtoveratrine A [143-57-7]; Up 200; 5uM; MCF7; HT_HG-U133A

DLK2 MDM2 EMID1 PML

5.52e-041964442800_UP
DrugHexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; MCF7; HT_HG-U133A

DZIP3 MDM2 ADA CYP26A1

5.52e-041964444965_DN
DrugGSK-3 Inhibitor IX; Down 200; 0.5uM; MCF7; HT_HG-U133A

DZIP3 ETNK2 CYP26A1 EMID1

5.52e-041964447044_DN
DrugFluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; HL60; HT_HG-U133A

PTPN2 PTPN4 ADA PML

5.52e-041964443032_DN
DrugTroleandomycin [2751-09-9]; Down 200; 5uM; PC3; HT_HG-U133A

MDM2 GRM4 HDAC7 PML

5.52e-041964443985_DN
DrugAmpyrone [83-07-8]; Down 200; 19.6uM; MCF7; HT_HG-U133A

FBXO41 MDM2 ETNK2 PML

5.52e-041964442249_DN
DrugZimelidine dihydrochloride monohydrate [61129-30-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A

FBXO41 PTPN2 ZNF133 CYP26A1

5.52e-041964445670_DN
DrugBeclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; MCF7; HT_HG-U133A

DLK2 MDM2 EMID1 PML

5.52e-041964444403_DN
Drug(+) -Levobunolol hydrochloride [47141-41-3]; Up 200; 12.2uM; HL60; HT_HG-U133A

DRP2 EMID1 DOK3 PML

5.52e-041964443016_UP
DrugPentetic acid [67-43-6]; Down 200; 10.2uM; HL60; HT_HG-U133A

ZFYVE26 MDM2 ADA HDAC7

5.52e-041964443049_DN
Drugpentamidine isethionate salt; Down 200; 100uM; MCF7; HG-U133A

DRP2 CYP26A1 EMID1 PWP2

5.63e-04197444639_DN
DrugGelsemine [509-15-9]; Up 200; 12.4uM; PC3; HT_HG-U133A

MDM2 HDAC7 RNF43 ETNK2

5.63e-041974444097_UP
DrugDichlorphenamide [120-97-8]; Down 200; 13.2uM; HL60; HT_HG-U133A

REC8 MDM2 ADA PML

5.63e-041974443027_DN
DrugPropafenone hydrochloride [34183-22-7]; Down 200; 10.6uM; MCF7; HT_HG-U133A

PTPN2 RNF31 MDM2 EMID1

5.63e-041974445437_DN
DrugEquilin [474-86-2]; Down 200; 15uM; HL60; HT_HG-U133A

REC8 ADA NME8 PML

5.63e-041974443039_DN
DrugFuraltadone hydrochloride [3759-92-0]; Up 200; 11uM; MCF7; HT_HG-U133A

REC8 MGAT5 RNF43 PML

5.63e-041974443413_UP
DrugProgesterone [57-83-0]; Up 200; 12.8uM; MCF7; HT_HG-U133A

REC8 DLK2 FBXO41 PML

5.63e-041974444992_UP
DrugLetrozole [112809-51-5]; Up 200; 14uM; PC3; HT_HG-U133A

REC8 CFH PIWIL2 PML

5.63e-041974444240_UP
Drugprazosin hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA

ZNF133 MDM2 GRM4 PRAME

5.63e-04197444826_UP
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

RNF31 BRF2 PML DNMT3B

5.63e-041974441183_DN
DrugNisoxetine hydrochloride [57754-86-6]; Up 200; 13uM; HL60; HT_HG-U133A

REC8 FBXO41 PIWIL2 DOK3

5.63e-041974443117_UP
DrugCalciferol [50-14-6]; Up 200; 10uM; MCF7; HT_HG-U133A

FBXO41 MDM2 HDAC7 PML

5.63e-041974443304_UP
DrugLansoprazole [103577-45-3]; Down 200; 10.8uM; MCF7; HT_HG-U133A

DZIP3 RNF43 BRF2 PML

5.63e-041974443529_DN
DrugDydrogesterone [152-62-5]; Down 200; 12.8uM; MCF7; HT_HG-U133A

MDM2 HDAC7 CYP26A1 BRF2

5.63e-041974444836_DN
DrugMetoclopramide monohydrochloride [7232-21-5]; Up 200; 11.8uM; HL60; HT_HG-U133A

MDM2 ADA DOK3 PML

5.63e-041974442353_UP
DrugGuanadrel sulfate [22195-34-2]; Down 200; 7.6uM; MCF7; HT_HG-U133A

FBXO41 MDM2 CYP26A1 PML

5.63e-041974444720_DN
DrugAlthiazide [5588-16-9]; Up 200; 10.4uM; MCF7; HT_HG-U133A

UMOD MGAT5 PRAME PML

5.63e-041974446089_UP
DrugFluorocurarine chloride [22273-09-2]; Up 200; 11.6uM; MCF7; HT_HG-U133A

PTPN2 MTA1 RNF43 BRF2

5.63e-041974446219_UP
DrugLevopropoxyphene napsylate [5714-90-9]; Down 200; 7.4uM; HL60; HT_HG-U133A

FBXO41 MDM2 HDAC7 PML

5.63e-041974442980_DN
DrugMyricetin [529-44-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

PTPN2 ETNK2 EMID1 PML

5.63e-041974443270_DN
Diseaseuromodulin measurement

CFH UMOD MGAT5

6.81e-0626423EFO_0021778
Diseasemitogen-activated protein kinase 12 measurement

CFH HDAC10

1.18e-054422EFO_0020576
Disease(N(1) + N(8))-acetylspermidine measurement

ATP13A4 HDAC10

2.96e-056422EFO_0800091
Diseasevascular cell adhesion protein 1 measurement

CFH MGAT5

4.13e-057422EFO_0020846
Diseaseacute myeloid leukemia (is_marker_for)

MDM2 PRAME DNMT3B

4.72e-0549423DOID:9119 (is_marker_for)
Diseaseprotein-tyrosine kinase 6 measurement

CFH UGT1A10

7.08e-059422EFO_0020691
Diseasetestis-specific chromodomain protein Y 1 measurement

CFH UGT1A10

7.08e-059422EFO_0802127
Diseasehemopexin measurement

CFH CRB1

1.08e-0411422EFO_0008149
Diseasebiliverdin measurement

GRM4 UGT1A10

1.29e-0412422EFO_0021033
Diseaseretinol dehydrogenase 16 measurement

CFH UGT1A10

1.53e-0413422EFO_0802007
DiseaseProstatic Neoplasms

REC8 RNF31 MDM2 RNF43 PML DNMT3B

2.24e-04616426C0033578
DiseaseMalignant neoplasm of prostate

REC8 RNF31 MDM2 RNF43 PML DNMT3B

2.24e-04616426C0376358
Diseaseidiopathic scoliosis (implicated_via_orthology)

DNAH10 SSPOP

2.34e-0416422DOID:0060250 (implicated_via_orthology)
Diseaseserum iron measurement

ATP13A4 MGAT5 DNMT3B

2.53e-0486423EFO_0006332
Diseaselow density lipoprotein cholesterol measurement, body fat percentage

DNAH10 UGT1A10

2.65e-0417422EFO_0004611, EFO_0007800
DiseaseAntibody Deficiency Syndrome

CFH DNMT3B

2.65e-0417422C0003257
Diseaseangiopoietin-related protein 1 measurement

CFH UGT1A10

2.98e-0418422EFO_0801382
DiseaseSarcoma

MDM2 PRAME

4.08e-0421422C1261473
Diseasetissue factor measurement

CFH UGT1A10

4.08e-0421422EFO_0010623
DiseaseImmunologic Deficiency Syndromes

CFH DNMT3B

4.91e-0423422C0021051
Diseasechronic myeloid leukemia (is_marker_for)

PRAME DNMT3B

6.79e-0427422DOID:8552 (is_marker_for)
Diseasecomplement factor H-related protein 2 measurement

CFH CRB1

7.84e-0429422EFO_0600055
Diseasecolorectal adenocarcinoma (is_implicated_in)

DOK3 DNMT3B

1.14e-0335422DOID:0050861 (is_implicated_in)
Diseasemultiple myeloma (is_marker_for)

PRAME PML

1.21e-0336422DOID:9538 (is_marker_for)
DiseaseAgents acting on the renin-angiotensin system use measurement

HDAC7 PCDH18 RNF43 CYP26A1

1.30e-03335424EFO_0009931

Protein segments in the cluster

PeptideGeneStartEntry
PCWVCGSLPVTNTME

ERVPABLB-1

81

P60509
ILCCMRHQPNWSPKV

ADA

151

P00813
PWSCYMCLPQRCHGV

DNMT3B

521

Q9UBC3
LPWGPLCAAMASCHS

ATP13A4

521

Q4VNC1
MHWPGSGQQLPRSIC

GRM4

506

Q14833
CMENGWSPTPRCIRV

CFH

431

P08603
RAHCWECPMVQPPER

REC8

326

O95072
TQGPLPNTCCHFWLM

PTPN2

86

P17706
CQGPLPHTCTDFWQM

PTPN4

726

P29074
ECRVLGHSDQCWMPP

PCDH18

921

Q9HCL0
CHGQVMWPPLSALQV

MGAT5

626

Q09328
LRRHTPCPQCSWGME

ETNK2

16

Q9NVF9
HRQAWMGPICQLAFP

DOK3

166

Q7L591
LGRMLHTPPVLQNCW

PRSS54

151

Q6PEW0
AQCIRPWLMQQGTCP

DZIP3

1171

Q86Y13
PWLMQQGTCPTCRLH

DZIP3

1176

Q86Y13
TLMCQQAHGLPLPAW

ACP4

211

Q9BZG2
RGQLEPQWKMLQCHP

HDAC10

651

Q969S8
CVLITCRQHNWPLTM

BRF2

121

Q9HAW0
SNRCLQMIGRCWPHL

FBXO41

731

Q8TF61
RHCDWQLLNGPPTMK

CYP26A1

461

O43174
CGVPACSHVPMWSAR

CRIPAK

236

Q8N1N5
CGVPACSHVPMWSAR

CRIPAK

256

Q8N1N5
CGVPACSHVPMWSAR

CRIPAK

276

Q8N1N5
CRCGVPACSHVPMWS

CRIPAK

336

Q8N1N5
QRVLQNCPWPMSCPG

EMID1

56

Q96A84
VRMPGCQHGTCHQPW

DLK2

61

Q6UY11
GCMQRLASCPDSWVP

HDAC7

896

Q8WUI4
LMPLCWSKPCHNNAT

CRB1

301

P82279
HFVRWMNGSCIECPP

DNAH10

931

Q8IVF4
MQGCPYTLPRCHDWQ

DRP2

6

Q13474
PWSPCDMCLGQSHRS

SSPOP

3481

A2VEC9
RPSMVWLSANPCPHC

PRAME

476

P78395
PSQCQAVRMPGCWPQ

PIWIL2

16

Q8TC59
LEASGMQCPICQAPW

PML

81

P29590
MNPPLPSHCNRCWAL

MDM2

311

Q00987
PWLHQHRTCPLCMFN

RNF43

301

Q68DV7
WCTLIPLSCFPNNMP

SLCO6A1

326

Q86UG4
CCLADLPQSIGMWTP

TDRD7

771

Q8NHU6
SWGPPNMQCRLCASC

MTA1

406

Q13330
GWVCVMCNRTSSPIP

RNF31

426

Q96EP0
MARAGWTSPVPLCVC

UGT1A10

1

Q9HAW8
TCVPVLRCNTAAPMW

UMOD

216

P07911
QAWCGPCRAMQPLFR

NME8

36

Q8N427
VLCMWQCDTPPEGLR

PWP2

211

Q15269
MQHVLCNHPPWIFTC

ZNF133

96

P52736
MRLCLIPWNTGTPQR

nan

1

A8MUA0
WTPCPRMCQAGNATV

THSD7B

746

Q9C0I4
WSKCPQSCDPHTMQR

THSD7B

1136

Q9C0I4
IQGVRWHCQDCPPEM

ZZZ3

831

Q8IYH5
PPRCSITELLQMCWP

ZFYVE26

1056

Q68DK2